#United States #Boston #Haemonetics #Investors Conference #Chris Simon

Haemonetics Corporation to Participate in Raymond James Conference

On March 2, 2026, Chris Simon, the President and CEO of Haemonetics Corporation, will take part in a fireside chat aimed at investors during the 47th Annual Institutional Investors Conference organized by Raymond James. The session is scheduled to begin at 10:25 AM ET and aims to provide valuable insights into the workings and future strategies of the company.

Live Webcast for Public Access

For those who are interested in tuning in, Haemonetics will offer a live webcast of the discussion, accessible through their Investor Relations webpage. This presents an excellent opportunity for current and potential investors to gain firsthand information about the company from its leadership. The link to the webcast will be available prior to the event, ensuring that attendees can easily access it from the comfort of their homes or offices.

Replay Availability

If you're unable to attend the live session, don't worry! Haemonetics plans to provide a recorded version of the webcast. This replay will be available approximately 12 hours after the live event has concluded and can be accessed for a duration of 90 days. This extended availability allows for thorough digesting of the information discussed, enabling investors to form informed opinions based on the insights shared by Simon.

About Haemonetics Corporation

Haemonetics is a prominent global medical technology enterprise committed to enhancing healthcare quality, efficiency, and effectiveness. Their innovative solutions target critical medical needs across various domains within the healthcare industry

Their offerings include advanced hospital technologies designed to enhance standards of care and patient outcomes, comprehensive plasma collection solutions aimed at optimizing operational capabilities for plasma centers, and products that assist blood collection centers in obtaining necessary blood components efficiently. Haemonetics has established a reputation for delivering excellence by consistently addressing the challenges faced in medical facilities, thereby transforming patient care experiences.

To learn more about their initiatives and corporate contributions, visit Haemonetics.

Contact Information

For those seeking additional information regarding the event or Haemonetics' solutions, the Investor Relations department can be reached directly. Contact Olga Guyette, Vice President of Investor Relations, or David Trenk, Manager of Investor Relations, via the following numbers:

• - Olga Guyette: (781) 356-9763
• - David Trenk: (203) 733-4987

They also welcome inquiries via email, providing robust support to stakeholders.

Moreover, Josh Gitelson, the Sr. Director of Global Communications, is available for media inquiries at (781) 356-9776. These contacts ensure that all interested parties can engage with the right representatives to gather the information they need.

Closing Thoughts

The participation of Haemonetics at the Raymond James Conference signifies their ongoing commitment to transparency and engagement with the investment community. This event is particularly important as it not only showcases the company’s achievements but also allows for dialogue regarding future aspirations and strategies, all of which contribute to the ever-evolving landscape of healthcare technology.